Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

Abstract : Carcinomas of an unknown primary site (CUP) are heterogeneous tumours with a median survival of only 8 months. Tyrosine kinase inhibitors are promising new drugs. The aim of this study was to determine the expression of EGF-receptor, Her-2/neu, and c-Kit tyrosine kinases in CUP. Paraffin-embedded specimens were obtained from 54 patients with a CUP who were included in the GEFCAPI 01 randomised phase II trial. Immunohistochemistry was performed using the Dako autostainer with antibodies directed against HER-2/neu protein, EGFR protein, and c-Kit protein (CD117). EGFR expression was found in 36 out of 54 samples (66%). In contrast, Her-2/neu overexpression and c-Kit positivity were only detected in 4 and 10% of patients, respectively. No significant association was found between the expression of the tyrosine kinase receptors and prognosis. EGFR expression was significantly associated with response to cisplatin-based chemotherapy: the response rates were 50 and 22% in patients with EGFR-positive tumours and EGFR-negative tumours, respectively (P<0.05). This study shows that EGFR is frequently expressed in CUP. This finding may prompt clinical trials investigating EGFR inhibitors in this setting. In contrast, c-Kit expression and Her-2/neu overexpression occur infrequently in CUP. EGFR expression was correlated to tumour chemosensitivity.
Type de document :
Article dans une revue
British Journal of Cancer, Cancer Research UK, 2007, 97 (7), pp.857-61. 〈10.1038/sj.bjc.6603942〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00479742
Contributeur : Philippe Saas <>
Soumis le : dimanche 2 mai 2010 - 14:43:05
Dernière modification le : lundi 9 juillet 2018 - 13:12:02

Lien texte intégral

Identifiants

Citation

C. Massard, J.-J. Voigt, A. Laplanche, Stéphane Culine, A. Lortholary, et al.. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?. British Journal of Cancer, Cancer Research UK, 2007, 97 (7), pp.857-61. 〈10.1038/sj.bjc.6603942〉. 〈inserm-00479742〉

Partager

Métriques

Consultations de la notice

171